A Pugatch Consilium study released today commissioned by the Biotechnology Innovation Organization (BIO) highlights strategies, policies and best practices that have been successful in creating an environment in which biotechnology innovation can flourish around the world.

The fifth edition of the Building the Bioeconomy report shows the correlation between economies with pro-innovation policy frameworks and those achieving strong biotechnology outputs. By examining 28 different indicators ranging from public policy inputs to biotechnology outputs, the report provides a full and detailed ...

Professor Meir Pugatch spoke at the St. Petersburg International Economic Forum (SPIEF) in the panel: “Life Sciences in 2030: A New Era for Biotechnology” which took place on May 26, 2018 and included the Deputy Ministers of the Ministries of Health, Industry and Trade, and Agriculture of the Russian Federation, as well as Senior Executives of top MNCs in the private sector. Prof. Pugatch presented key highlights of Pugatch Consilium’s research concerning the enabling conditions for developing a competitive bioeconomy ...

Professor Meir Pugatch spoke today at the forum “Positioning Taiwan as an Asia-Pacific Biomedical R&D Hub” which took place the International Convention Center in Taipei, and included the Vice President of Taiwan and additional government officials.

Professor Pugatch presented a comprehensive analysis of Taiwan’s competitiveness in the biotech sector, as well as recent improvements to and remaining challenges in Taiwan’s path to leadership in global biotech innovation.

By utilizing a competitive mentality that views policy as instrumental in achieving economic and societal ...

Professor Meir Pugatch spoke yesterday at the event: “Building a sustainable Policy Framework for Biologics and Biosimilar Medicines in Europe”, which took place at the European Parliament, and included members from the European Commission and organizations such as Medicines for Europe, ESMO and EPF. Professor Pugatch presented the findings of a new study by Pugatch Consilium, commissioned by the European Federation of Pharmaceutical Industries and Associations (EFPIA).

With 38 biosimilar medicines approved and marketed and hundreds of clinical trials on ...

Pugatch Consilium unveiled at the Financial Times Latin America Healthcare & Life Sciences Summit in Sao Paulo Brazil the 2017 Biopharmaceutical Competitiveness & Investment (BCI) Latin America Special Report. This Report is derived from the main 2017 BCI Survey, a global executive opinion survey and index that measures the relative attractiveness of economies to investment from biopharmaceutical research-based companies.

Does the EU Commission really think weakening IP incentives for biopharmaceutical innovation in Europe is going to create more jobs and economic activity?

by Dr David Torstensson, Partner, Pugatch Consilium

As an industry the research-based biopharmaceutical sector is one of Europe’s biggest success stories. Companies like Novartis, Roche, Sanofi Aventis, Novo Nordisk, AstraZeneca and GSK are some of the largest, most innovative and successful research-based biopharmaceutical companies in the world. Not only do these companies have a long track record of producing ...

Pugatch Consilium has released the 2017 Biopharmaceutical Competitiveness & Investment (BCI) Survey. An executive opinion survey, in 2017 the BCI polled business leaders and local general managers from the biopharmaceutical industry about the investment environment in 31 markets. The results are available in the linked report below.

The headline results of the 2017 BCI Survey include:

The policy environment matters a great deal for biopharmaceutical investment decisions. Economies with policies supporting biopharmaceutical innovation and investment are much more likely to actually secure ...